These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22167108)

  • 1. Commentary on Anand et al.
    Dixon DO
    Clin Trials; 2011 Dec; 8(6):720-1; discussion 726. PubMed ID: 22167108
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on Anand et al.
    Califf RM
    Clin Trials; 2011 Dec; 8(6):724-5; discussion 726. PubMed ID: 22167110
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on Anand et al.
    DeMets DL
    Clin Trials; 2011 Dec; 8(6):722-3; discussion 726. PubMed ID: 22167109
    [No Abstract]   [Full Text] [Related]  

  • 4. What information should a sponsor of a randomized trial receive during its conduct?
    Anand SS; Wittes J; Yusuf S
    Clin Trials; 2011 Dec; 8(6):716-9. PubMed ID: 22024103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical issues with the disclosure of surgical trial short-term data.
    Allardyce RA; Bagshaw PF; Frampton CM; Frizelle FA; Hewett PJ; Rieger NA; Smith JS; Solomon MJ; Stevenson AR
    ANZ J Surg; 2011 Mar; 81(3):125-31. PubMed ID: 21342382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data monitoring (and safety) committees--what are they and why do we need them? Primary Care Alliance for Clinical Trials (PACT) Network.
    Pirotta M; Chondros P;
    Aust Fam Physician; 2004 Nov; 33(11):950-1, 956. PubMed ID: 15584339
    [No Abstract]   [Full Text] [Related]  

  • 7. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 8. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The statistician and the data monitoring committee.
    D'Agostino RB
    Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
    [No Abstract]   [Full Text] [Related]  

  • 10. [Statement on Porzsolt in "monitor healthcare research"].
    Rettig-Stürmer G; Schieffer H; Müller E
    Urologe A; 2014 Mar; 53(3):390. PubMed ID: 23979444
    [No Abstract]   [Full Text] [Related]  

  • 11. Monitoring clinical trials. Interim data should not be publicly available.
    Richards SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11778588
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring clinical trials. Several points are contentious.
    Parry D
    BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778590
    [No Abstract]   [Full Text] [Related]  

  • 13. Data monitoring committees and stopping trials-Giving participants a voice.
    Trachtman H; Caplan A
    Contemp Clin Trials; 2018 May; 68():146. PubMed ID: 29567282
    [No Abstract]   [Full Text] [Related]  

  • 14. Monitoring clinical trials. Dissemination of decisions on interim analyses needs wider debate.
    Bird SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11744570
    [No Abstract]   [Full Text] [Related]  

  • 15. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 16. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Setting the RECORD Straight.
    Nissen SE
    JAMA; 2010 Mar; 303(12):1194-5. PubMed ID: 20332408
    [No Abstract]   [Full Text] [Related]  

  • 18. The dilemma of data-safety monitoring: provision of significant new data to research participants.
    Peppercorn J; Buss WG; Fost N; Godley PA
    Lancet; 2008 Feb; 371(9611):527-9. PubMed ID: 18262043
    [No Abstract]   [Full Text] [Related]  

  • 19. Ensuring integrity in industry-sponsored research: primum non nocere, revisited.
    DeAngelis CD; Fontanarosa PB
    JAMA; 2010 Mar; 303(12):1196-8. PubMed ID: 20332409
    [No Abstract]   [Full Text] [Related]  

  • 20. What must research subjects be told regarding the results of completed randomized trials?
    Markman M
    IRB; 2004; 26(3):8-10. PubMed ID: 15281194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.